請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4936
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 何佳安(Ja-an Ho) | |
dc.contributor.author | Song-Ling Wong | en |
dc.contributor.author | 翁松翎 | zh_TW |
dc.date.accessioned | 2021-05-15T17:50:28Z | - |
dc.date.available | 2019-09-05 | |
dc.date.available | 2021-05-15T17:50:28Z | - |
dc.date.copyright | 2014-09-05 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-20 | |
dc.identifier.citation | 1. Neuse, E. W. (2008) Synthetic Polymers as Drug-Delivery Vehicles in Medicine, Metal-Based Drugs 2008.
2. Allen, T. M., and Cullis, P. R. (2004) Drug Delivery Systems: Entering the Mainstream, Science 303, 1818-1822. 3. Straub, J. A., Chickering, D. E., Lovely, J. C., Zhang, H., Shah, B., Waud, W. R., and Bernstein, H. (2005) Intravenous Hydrophobic Drug Delivery: A Porous Particle Formulation of Paclitaxel (AI-850), Pharmaceutical Research 22, 347-355. 4. Roden, D. M. (2012) Chapter 5. Principles of Clinical Pharmacology, In Harrison's Principles of Internal Medicine, 18e (Longo, D. L., Fauci, A. S., Kasper, D. L., Hauser, S. L., Jameson, J. L., and Loscalzo, J., Eds.), The McGraw-Hill Companies, New York, NY. 5. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Advanced Drug Delivery Reviews 23, 3-25. 6. Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., and Farokhzad, O. C. (2012) Targeted polymeric therapeutic nanoparticles: design, development and clinical translation, Chemical Society Reviews 41, 2971-3010. 7. Venturoli, D., and Rippe, B. (2005) Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability, American Journal of Physiology. Renal Physiology 288, F605-613. 8. Yuan, F. (1998) Transvascular drug delivery in solid tumors, Seminars in Radiation Oncology 8, 164-175. 9. Matsumura, Y., and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer research 46, 6387-6392. 10. Dvorak, H. F. (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 20, 4368-4380. 11. Guidi, A. J., Schnitt, S. J., Fischer, L., Tognazzi, K., Harris, J. R., Dvorak, H. F., and Brown, L. F. (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast, Cancer 80, 1945-1953. 12. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, Journal of Controlled Release : Official Journal of the Controlled Release Society 65, 271-284. 13. Lembo, D., and Cavalli, R. (2010) Nanoparticulate delivery systems for antiviral drugs, Antiviral Chemistry & Chemotherapy 21, 53-70. 14. Torchilin, V. P. (2005) Recent advances with liposomes as pharmaceutical carriers, Nature Reviews. Drug Discovery 4, 145-160. 15. Murakami, Y., Yokoyama, M., Okano, T., Nishida, H., Tomizawa, Y., Endo, M., and Kurosawa, H. (2007) A novel synthetic tissue-adhesive hydrogel using a crosslinkable polymeric micelle, Journal of Biomedical Materials Research. Part A 80, 421-427. 16. Ponta, A., and Bae, Y. (2010) PEG-poly(amino acid) block copolymer micelles for tunable drug release, Pharmaceutical research 27, 2330-2342. 17. Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., and Park, T. G. (2008) LHRH Receptor-Mediated Delivery of siRNA Using Polyelectrolyte Complex Micelles Self-Assembled from siRNA-PEG-LHRH Conjugate and PEI, Bioconjugate Chemistry 19, 2156-2162. 18. Al-Abd, A. M., Lee, S. H., Kim, S. H., Cha, J. H., Park, T. G., Lee, S. J., and Kuh, H. J. (2009) Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro, Journal of controlled release : official journal of the Controlled Release Society 137, 130-135. 19. Rajendran, R., Williams, C., Lappin, D. F., Millington, O., Martins, M., and Ramage, G. (2013) Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms, Eukaryotic cell 12, 420-429. 20. Yokoyama, M., Okano, T., Sakurai, Y., Suwa, S., and Kataoka, K. (1996) Introduction of cisplatin into polymeric micelle, Journal of Controlled Release 39, 351-356. 21. Yokoyama, M., Opanasopit, P., Okano, T., Kawano, K., and Maitani, Y. (2004) Polymer design and incorporation methods for polymeric micelle carrier system containing water-insoluble anti-cancer agent camptothecin, Journal of Drug Targeting 12, 373-384. 22. Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., and Park, T. G. (2008) Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer, Journal of controlled release : official journal of the Controlled Release Society 129, 107-116. 23. Patil, M. L., Zhang, M., Taratula, O., Garbuzenko, O. B., He, H., and Minko, T. (2009) Internally Cationic Polyamidoamine PAMAM-OH Dendrimers for siRNA Delivery: Effect of the Degree of Quaternization and Cancer Targeting, Biomacromolecules 10, 258-266. 24. Tomalia, D. A., Reyna, L. A., and Svenson, S. (2007) Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging, Biochemical Society Transactions 35, 61-67. 25. Cartiera, M. S., Johnson, K. M., Rajendran, V., Caplan, M. J., and Saltzman, W. M. (2009) The uptake and intracellular fate of PLGA nanoparticles in epithelial cells, Biomaterials 30, 2790-2798. 26. Kocbek, P., Obermajer, N., Cegnar, M., Kos, J., and Kristl, J. (2007) Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody, Journal of Controlled Release : Official Journal of the Controlled Release Society 120, 18-26. 27. Zhang, L., Chan, J. M., Gu, F. X., Rhee, J.-W., Wang, A. Z., Radovic-Moreno, A. F., Alexis, F., Langer, R., and Farokhzad, O. C. (2008) Self-Assembled Lipid−Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform, ACS Nano 2, 1696-1702. 28. Adiseshaiah, P. P., Hall, J. B., and McNeil, S. E. (2010) Nanomaterial standards for efficacy and toxicity assessment, Wiley interdisciplinary reviews. Nanomedicine and Nanobiotechnology 2, 99-112. 29. Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., and Farokhzad, O. C. (2012) Targeted polymeric therapeutic nanoparticles: design, development and clinical translation, Chemical Society Reviews 41, 2971-3010. 30. Hilgenbrink, A. R., and Low, P. S. (2005) Folate receptor-mediated drug targeting: from therapeutics to diagnostics, Journal of Pharmaceutical Sciences 94, 2135-2146. 31. Zhao, X., Li, H., and Lee, R. J. (2008) Targeted drug delivery via folate receptors, Expert Opinion on Drug Delivery 5, 309-319. 32. Lu, Y., Sega, E., and Low, P. S. (2005) Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells, International Journal of Cancer. Journal International du Cancer 116, 710-719. 33. Chen, H., Ahn, R., Van den Bossche, J., Thompson, D. H., and O'Halloran, T. V. (2009) Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide, Molecular Cancer Therapeutics 8, 1955-1963. 34. Xia, W., and Low, P. S. (2010) Folate-targeted therapies for cancer, Journal of Medicinal Chemistry 53, 6811-6824. 35. Xu, L., Pirollo, K. F., Tang, W. H., Rait, A., and Chang, E. H. (1999) Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts, Human Gene Therapy 10, 2941-2952. 36. Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., and Penichet, M. L. (2006) The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer, Clinical Immunology (Orlando, Fla.) 121, 144-158. 37. Xu, L., Pirollo, K. F., and Chang, E. H. (1997) Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro, Human Gene Therapy 8, 467-475. 38. de Bruin, K., Ruthardt, N., von Gersdorff, K., Bausinger, R., Wagner, E., Ogris, M., and Brauchle, C. (2007) Cellular Dynamics of EGF Receptor-Targeted Synthetic Viruses, Molecular Therapy 15, 1297-1305. 39. Carlsson, J., Blomquist, E., Gedda, L., Liljegren, A., Malmstrom, P. U., Sjostrom, A., Sundin, A., Westlin, J. E., Zhao, Q., Tolmachev, V., and Lundqvist, H. (1999) Conjugate chemistry and cellular processing of EGF-dextran, Acta Oncologica (Stockholm, Sweden) 38, 313-321. 40. Odrljin, T. M., Haidaris, C. G., Lerner, N. B., and Simpson-Haidaris, P. J. (2001) Integrin alphavbeta3-mediated endocytosis of immobilized fibrinogen by A549 lung alveolar epithelial cells, American Journal of Respiratory Cell and Molecular Biology 24, 12-21. 41. Cheng, S.-H., Lee, C.-H., Chen, M.-C., Souris, J. S., Tseng, F.-G., Yang, C.-S., Mou, C.-Y., Chen, C.-T., and Lo, L.-W. (2010) Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics-the trio of imaging, targeting and therapy, Journal of Materials Chemistry 20, 6149-6157. 42. Lu, J., Shi, M., and Shoichet, M. S. (2009) Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors, Bioconjugation Chemistry 20, 87-94. 43. Xu, L., Huang, C. C., Huang, W., Tang, W. H., Rait, A., Yin, Y. Z., Cruz, I., Xiang, L. M., Pirollo, K. F., and Chang, E. H. (2002) Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes, Molecular Cancer Therapeutics 1, 337-346. 44. Santra, S., Kaittanis, C., Grimm, J., and Perez, J. M. (2009) Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging, Small (Weinheim an der Bergstrasse, Germany) 5, 1862-1868. 45. Das, M., Mishra, D., Dhak, P., Gupta, S., Maiti, T. K., Basak, A., and Pramanik, P. (2009) Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging, Small (Weinheim an der Bergstrasse, Germany) 5, 2883-2893. 46. Huang, P., Li, Z., Lin, J., Yang, D., Gao, G., Xu, C., Bao, L., Zhang, C., Wang, K., Song, H., Hu, H., and Cui, D. (2011) Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy, Biomaterials 32, 3447-3458. 47. Cho, H., and Kwon, G. S. (2011) Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging, ACS Nano 5, 8721-8729. 48. Xu, H., Cheng, L., Wang, C., Ma, X., Li, Y., and Liu, Z. (2011) Polymer encapsulated upconversion nanoparticle/iron oxide nanocomposites for multimodal imaging and magnetic targeted drug delivery, Biomaterials 32, 9364-9373. 49. Na, J. H., Koo, H., Lee, S., Min, K. H., Park, K., Yoo, H., Lee, S. H., Park, J. H., Kwon, I. C., Jeong, S. Y., and Kim, K. (2011) Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models, Biomaterials 32, 5252-5261. 50. Santra, S., and Perez, J. M. (2011) Selective N-alkylation of beta-alanine facilitates the synthesis of a poly(amino acid)-based theranostic nanoagent, Biomacromolecules 12, 3917-3927. 51. Melancon, M. P., Elliott, A., Ji, X., Shetty, A., Yang, Z., Tian, M., Taylor, B., Stafford, R. J., and Li, C. (2011) Theranostics with multifunctional magnetic gold nanoshells: photothermal therapy and t2* magnetic resonance imaging, Investigative radiology 46, 132-140. 52. Ma, M., Chen, H., Chen, Y., Wang, X., Chen, F., Cui, X., and Shi, J. (2012) Au capped magnetic core/mesoporous silica shell nanoparticles for combined photothermo-/chemo-therapy and multimodal imaging, Biomaterials 33, 989-998. 53. Wang, L. S., Wu, L. C., Lu, S. Y., Chang, L. L., Teng, I. T., Yang, C. M., and Ho, J. A. (2010) Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding, ACS Nano 4, 4371-4379. 54. Kim, D., Jeong, Y. Y., and Jon, S. (2010) A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer, ACS Nano 4, 3689-3696. 55. Huang, P., Bao, L., Zhang, C., Lin, J., Luo, T., Yang, D., He, M., Li, Z., Gao, G., Gao, B., Fu, S., and Cui, D. (2011) Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy, Biomaterials 32, 9796-9809. 56. Lu, P. L., Chen, Y. C., Ou, T. W., Chen, H. H., Tsai, H. C., Wen, C. J., Lo, C. L., Wey, S. P., Lin, K. J., Yen, T. C., and Hsiue, G. H. (2011) Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery, Biomaterials 32, 2213-2221. 57. Moon, G. D., Choi, S. W., Cai, X., Li, W., Cho, E. C., Jeong, U., Wang, L. V., and Xia, Y. (2011) A new theranostic system based on gold nanocages and phase-change materials with unique features for photoacoustic imaging and controlled release, Journal of the American Chemical Society 133, 4762-4765. 58. Homan, K., Shah, J., Gomez, S., Gensler, H., Karpiouk, A., Brannon-Peppas, L., and Emelianov, S. (2010) Silver nanosystems for photoacoustic imaging and image-guided therapy, Journal of Biomedical Optics 15, 021316. 59. Singh, A., Dilnawaz, F., Mewar, S., Sharma, U., Jagannathan, N. R., and Sahoo, S. K. (2011) Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy, ACS Applied Materials & Interfaces 3, 842-856. 60. Chertok, B., David, A. E., and Yang, V. C. (2011) Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers, Biomaterials 32, 6245-6253. 61. Lim, E. K., Huh, Y. M., Yang, J., Lee, K., Suh, J. S., and Haam, S. (2011) pH-triggered drug-releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI, Advanced Materials (Deerfield Beach, Fla.) 23, 2436-2442. 62. Yallapu, M. M., Othman, S. F., Curtis, E. T., Gupta, B. K., Jaggi, M., and Chauhan, S. C. (2011) Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy, Biomaterials 32, 1890-1905. 63. Rastogi, R., Gulati, N., Kotnala, R. K., Sharma, U., Jayasundar, R., and Koul, V. (2011) Evaluation of folate conjugated pegylated thermosensitive magnetic nanocomposites for tumor imaging and therapy, Colloids and Surfaces. B, Biointerfaces 82, 160-167. 64. Foy, S. P., Manthe, R. L., Foy, S. T., Dimitrijevic, S., Krishnamurthy, N., and Labhasetwar, V. (2010) Optical Imaging and Magnetic Field Targeting of Magnetic Nanoparticles in Tumors, ACS Nano 4, 5217-5224. 65. Wang, L. S., Chuang, M. C., and Ho, J. A. (2012) Nanotheranostics--a review of recent publications, International Journal of Nanomedicine 7, 4679-4695. 66. Wallace, D. C. (2012) Mitochondria and cancer, Nat Rev Cancer 12, 685-698. 67. Lane, N. (2005) Power, sex, suicide : mitochondria and the meaning of life, Oxford University Press, New York. 68. Fulda, S., Galluzzi, L., and Kroemer, G. (2010) Targeting mitochondria for cancer therapy, Nature reviews. Drug discovery 9, 447-464. 69. Lee, J., Giordano, S., and Zhang, J. (2012) Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling, The Biochemical Journal 441, 523-540. 70. Circu, M. L., and Aw, T. Y. (2010) Reactive oxygen species, cellular redox systems, and apoptosis, Free Radical Biology & Medicine 48, 749-762. 71. Warburg, O. (1956) On the Origin of Cancer Cells, Science 123, 309-314. 72. Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., Shankar, L., Larson, S. M., Sigman, C. C., Schilsky, R. L., and Sullivan, D. C. (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 11, 2785-2808. 73. Pedersen, P. L. (2012) 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective 'small molecule' anti-cancer agent taken from labside to bedside: introduction to a special issue, Journal of Bioenergetics and Biomembranes 44, 1-6. 74. Hoye, A. T., Davoren, J. E., Wipf, P., Fink, M. P., and Kagan, V. E. (2008) Targeting Mitochondria, Accounts of Chemical Research 41, 87-97. 75. Marrache, S., and Dhar, S. (2012) Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics, Proceedings of the National Academy of Sciences 109, 16288-16293. 76. Marrache, S., Tundup, S., Harn, D. A., and Dhar, S. (2013) Ex Vivo Programming of Dendritic Cells by Mitochondria-Targeted Nanoparticles to Produce Interferon-Gamma for Cancer Immunotherapy, ACS Nano 7, 7392-7402. 77. Li, N., Zhang, C. X., Wang, X. X., Zhang, L., Ma, X., Zhou, J., Ju, R. J., Li, X. Y., Zhao, W. Y., and Lu, W. L. (2013) Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways, Biomaterials 34, 3366-3380. 78. Yu, Y., Wang, Z. H., Zhang, L., Yao, H. J., Zhang, Y., Li, R. J., Ju, R. J., Wang, X. X., Zhou, J., Li, N., and Lu, W. L. (2012) Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma, Biomaterials 33, 1808-1820. 79. Zhou, J., Zhao, W. Y., Ma, X., Ju, R. J., Li, X. Y., Li, N., Sun, M. G., Shi, J. F., Zhang, C. X., and Lu, W. L. (2013) The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer, Biomaterials 34, 3626-3638. 80. Ma, X., Zhang, L.-H., Wang, L.-R., Xue, X., Sun, J.-H., Wu, Y., Zou, G., Wu, X., Wang, P. C., Wamer, W. G., Yin, J.-J., Zheng, K., and Liang, X.-J. (2012) Single-Walled Carbon Nanotubes Alter Cytochrome c Electron Transfer and Modulate Mitochondrial Function, ACS Nano 6, 10486-10496. 81. Yoong, S. L., Wong, B. S., Zhou, Q. L., Chin, C. F., Li, J., Venkatesan, T., Ho, H. K., Yu, V., Ang, W. H., and Pastorin, G. (2014) Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin, Biomaterials 35, 748-759. 82. Grabar, K. C., Freeman, R. G., Hommer, M. B., and Natan, M. J. (1995) Preparation and Characterization of Au Colloid Monolayers, Analytical Chemistry 67, 735-743. 83. Chen, S.-H., Hsu, Y.-P., Lu, H.-Y., and Ho, J.-a. A. (2014) Gold/Phospholipid nanoconstructs as label-free optical probes for evaluating phospholipase A2 activity, Biosensors and Bioelectronics 52, 202-208. 84. Yang, S., Damiano, M. G., Zhang, H., Tripathy, S., Luthi, A. J., Rink, J. S., Ugolkov, A. V., T. K. Singh, A., Dave, S. S., Gordon, L. I., and Thaxton, C. S. (2013) Biomimetic, synthetic HDL nanostructures for lymphoma, Proceedings of the National Academy of Sciences 110, 2511-2516. 85. Lee, J.-S., Stoeva, S. I., and Mirkin, C. A. (2006) DNA-Induced Size-Selective Separation of Mixtures of Gold Nanoparticles, Journal of the American Chemical Society 128, 8899-8903. 86. Cuvillier, N., Millet, F., Petkova, V., Nedyalkov, M., and Benattar, J.-J. (2000) Structure of Freestanding Phospholipidic Bilayer Films, Langmuir 16, 5029-5035. 87. Ziblat, R., Leiserowitz, L., and Addadi, L. (2010) Crystalline domain structure and cholesterol crystal nucleation in single hydrated DPPC:cholesterol:POPC bilayers, Journal of the American Chemical Society 132, 9920-9927. 88. Hofsass, C., Lindahl, E., and Edholm, O. (2003) Molecular dynamics simulations of phospholipid bilayers with cholesterol, Biophysical Journal 84, 2192-2206. 89. He, Y. Q., Liu, S. P., Kong, L., and Liu, Z. F. (2005) A study on the sizes and concentrations of gold nanoparticles by spectra of absorption, resonance Rayleigh scattering and resonance non-linear scattering, Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy 61, 2861-2866. 90. Wang, L.-S., Wu, L.-C., Lu, S.-Y., Chang, L.-L., Teng, I. T., Yang, C.-M., and Ho, J.-a. A. (2010) Biofunctionalized Phospholipid-Capped Mesoporous Silica Nanoshuttles for Targeted Drug Delivery: Improved Water Suspensibility and Decreased Nonspecific Protein Binding, ACS Nano 4, 4371-4379. 91. Marrache, S., and Dhar, S. (2013) Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis, Proceedings of the National Academy of Sciences of the United States of America 110, 9445-9450. 92. Reers, M., Smith, T. W., and Chen, L. B. (1991) J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential, Biochemistry 30, 4480-4486. 93. Tanida, I., Ueno, T., and Kominami, E. (2008) LC3 and Autophagy, Methods in Molecular Biology (Clifton, N.J.) 445, 77-88. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4936 | - |
dc.description.abstract | 近年來,以粒線體為標的開發抗癌藥物成為新一代癌症治療的重要研究方向。粒線體是細胞的能量以及死亡的調控中心,且腫瘤細胞粒線體的功能普遍異常,因此針對腫瘤細胞和正常細胞在代謝以及死亡調控上的顯著差異尋找標的,是重要的新藥發展策略。目前已經有多種以粒線體為標靶的藥物進入到臨床試驗階段。
以奈米藥物載體攜帶抗癌藥物有下列優點:1)奈米藥物載體可以透過enhanced permeability and retention effect (EPR effect)使抗癌藥物累積在腫瘤,降低對正常組織及器官的副作用;2)可以使疏水性藥物均勻的分散在生物系統中,避免因使用助溶劑造成的副作用;3)可以在載體上做各種修飾增加不同功能(ex: targeting, imaging),而不用改變藥物的分子結構。基於上述奈米藥物載體的優點,及以癌細胞粒線體為標靶之化學治療策略的發展,開發能有效運送藥物至粒線體之藥物載體有其必要性。 在本研究中,我們利用修飾有triphenylphosphonium (TPP)分子之磷脂質來包覆金奈米粒子(phospholipid capped gold nanoparticles, PLGNP)表面,使其成為以粒線體為標靶之奈米粒子;並利用金奈米粒子可以透過感應耦合質譜儀(ICP-MS)準確量化的特點,來評估我們的修飾方法是否可以使奈米粒子有效地進入到粒線體。通過合成方法的最佳化,目前已經合成出適合用來做細胞實驗的PLGNP-TPP。下一步將會使癌細胞與PLGNP-TPP共培養後,分離出粒線體並用ICP-MS評估其進入到粒線體的效率。若ICP-MS測得的數據證明PLGNP-TPP可以有效地進入到粒線體,則此修飾策略將可應用到其他不同種類的奈米藥物載體上,並且PLGNP-TPP也有機會成為研究奈米粒子與粒線體功能等基本研究的重要工具。 本研究也嘗試利用有無粒線體標靶分子修飾之PLGNP來闡明金奈米粒子對粒線體功能的影響。在細胞存活率試驗(MTT assay)發現PLGNP-TPP會影響A549肺癌細胞的存活率,進一步測試和粒線體活性有關的指標,發現細胞中的ATP level下降,並有粒線體膜電位失常等現象。細胞中針對粒線體受損有一套處理的機制,受損的粒線體會被細胞自噬清除以維持細胞內整體粒線體的正常功能。觀察細胞自噬的marker ,即microtubule-associated protein 1light chain 3的表現後我們發現,與PLGNP-TPP共培養後的細胞有活化細胞自噬的現象。初步的結果顯示PLGNP-TPP會造成細胞中粒線體的受損,並開啟細胞中修復粒線體受損的機制。詳細的過程還需要更進一步研究,以判斷PLGNP-TPP或是其他以粒線體為標靶的奈米藥物載體在使用上需注意的事項或是所需要的改良。 | zh_TW |
dc.description.abstract | In recent years, targeting mitochondria as a therapeutic target has become an emerging strategy in cancer treatment. Mitochondria are often referred to as a central hub for responses to cellular stress and cell injury; in addition, the well-established functions of mitochondria in energy supply/storage and apoptosis provide novel targets for tumor cell suicide. Therefore the alterations in cancer cells that protect cell from apoptosis can be utilized to inhibit proliferation of cancer cell. Furthermore, strategies of re-programming in cancer cells with metabolic differences from their normal counterparts may lead to alternative therapeutic approaches. Currently there are several drug candidates that are attempted to use in targeting mitochondria are in cancer clinical trials.
Nanodrugs are known to offer several key features, including: (i) site-directing nanodrug can be found to accumulate intensively in tumor site by enhanced permeability and retention effect (EPR effect), avoiding or minimizing side effects to the normal tissue; (ii) improved pharmacokinetic profile for drugs with poor solubility; (iii) versatility of nanodrugs (can be designed to obtain mutli-functions, including imaging, hyperthermia, stimuli-controlled release). Considering the great potential offered by mitochondrially-targeted nanodrugs, the development of a reliable mitochondria-targeted nanocarrier is desirable. In this study, the unique characteristics of triphenylphosphonium (TPP) was exploited to design a mitochondrial targeting nanodrug. It was achieved by developing a facile synthetic strategy to conjugate this mitochondria-targeted moiety onto the phospholipid layer of the gold nanoparticles functionalized with phospholipids | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T17:50:28Z (GMT). No. of bitstreams: 1 ntu-103-R01b22023-1.pdf: 3660494 bytes, checksum: e337edaf0b7af50fa4a716eaf86ba202 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 目錄
謝誌 i 中文摘要 ii Abstract iv 圖目錄 viii 表目錄 x 第一章 緒論 1 第二章 文獻回顧 3 2.1 藥物動力學 3 2.2 奈米藥物載體 5 2.2.1 奈米藥物載體的發展現況 8 2.3 粒線體 11 2.3.1 粒線體與癌症 17 2.3.2 以粒線體為標靶之奈米藥物載體文獻回顧 21 2.4 結語 23 第三章 實驗藥品與儀器 24 3.1 實驗藥品 (Chemicals and reagents) 24 3.2 實驗儀器 (Apparatus) 27 3.3 癌細胞株 (Cancer cell lines) 27 第四章 製備方法與鑑定 28 4.1 DSPE-PEG2000-TPP conjugate 合成 28 4.2 金奈米粒子製備 30 4.3 脂質包覆之金奈米粒子之製備 31 4.3. 細胞實驗 33 4.3.1 細胞存活率測試 33 4.3.2 偵測細胞內ATP含量 34 4.3.3 粒線體膜電位之觀測 35 4.3.4 細胞內酸性胞器染色 35 4.3.5 西方點墨法 36 第五章 結果與討論 40 5.1 DSPE-PEG2000-TPP conjugate 合成與鑑定 40 5.2脂質包覆之金奈米粒子之製備與鑑定 42 5.3脂質包覆之金奈米粒子之穩定性測試 47 5.4 PLGNP-TPP 造成細胞存活率下降 49 5.5 PLGNP-TPP 造成細胞內ATP含量下降 51 5.6粒線體膜電位之觀測 53 5.7 PLGNP-TPP 活化細胞自噬 55 5.8 結論與未來展望 57 參考文獻 58 | |
dc.language.iso | zh-TW | |
dc.title | 開發以粒線體為標靶之奈米藥物載體 | zh_TW |
dc.title | Development of nano drug carriers targeting mitochondria | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 洪嘉呈(Jia-Cheng Horng),楊家銘(Chia-Min Yang),吳立真(Li-chen Wu),徐士蘭(Shih-Lan Hsu) | |
dc.subject.keyword | 奈米藥物載體,粒線體,藥物傳遞,金奈米粒子, | zh_TW |
dc.subject.keyword | nano drug carrier,mitochondria,drug delivery,gold nanoparticles, | en |
dc.relation.page | 71 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-08-20 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 3.57 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。